Udai Banerji
udaibanerji.bsky.social
Udai Banerji
@udaibanerji.bsky.social
Clinician Scientist, passionate translational medicine and drug discovery in oncology and beyond...
Fuelling the qest for the next generation of clinician scientists. Great opportunity!
❗One week left to apply for our intercalated #PhD (iPhD) ⌛

If you're a medical student interested in becoming a clinician-scientist, check out our PhD projects for 2026. 👇
🩺 Are you a #MedStudent doing an iBSc? We're looking for future clinician-scientists to join our intercalated #PhD ( #iPhD) programme in 2026.

Explore projects & apply by 20 Nov 👉 bit.ly/48YA5Tp

Please share with your networks!

#CancerResearch #ConvergenceScience #CRUKFunded
November 13, 2025 at 6:52 PM
PhD convocation ceremony at @icr.ac.uk with DrDr Alvaro Graces. His thesis entitled Clonal Dynamics and evolutionary pathways in high grade serous ovarian cancer under therapeutic pressure siggests our current use of chemotherapy can be better optimised. @trevorgraham.bsky.social
November 1, 2025 at 12:32 PM
Interesting insights into phase I trial recruitment in oncology and health care utilization using data extracted from unstructured text in health care records. pubmed.ncbi.nlm.nih.gov/40855012/ @icr.ac.uk @royalmarsden.org @ecmc-uk.bsky.social @crukconvergence.bsky.social @nihr.bsky.social
August 29, 2025 at 1:43 PM
Organoid culture is prohibitively expensive. Solution to Harvest Organoids Efficiently (SHOE) allows rapid and inexpensive harvesting of organoids. Please use in your research labs and cite. pubmed.ncbi.nlm.nih.gov/40641211/ @icr.ac.uk @royalmarsden.org @crukconvergence.bsky.social
July 14, 2025 at 4:09 PM
Antibody-drug-conjugate toxicity is real and poorly understood. Looking for trends in association with antibody/linker/payloads. pubmed.ncbi.nlm.nih.gov/40611310/ @icr.ac.uk @royalmarsden.org @ecmc-uk.bsky.social @crukconvergence.bsky.social
July 8, 2025 at 10:08 AM
June 27, 2025 at 10:48 AM
Published today in @natmed.nature.com www.nature.com/articles/s41... combination of avutometinib and defactinib in LGSOC. @icr.ac.uk@icrdduiit.bsky.social@icr-ctsu.bsky.social @royalmarsden.org @ecmc-uk.bsky.social
@nihr.bsky.social‬ ‪@crukconvergence.bsky.social @cancerresearchuk.org

June 27, 2025 at 10:40 AM
#MCCR2025. Methods in clinical cancer research workshop hits its 25 year birthday! Fabulous opportunity to train young oncologists to develop research protocols. Especially proud to have been a trainee over 20 years ago and having served as faculty. @ESMO @EORTC @theaacr.bsky.social
June 19, 2025 at 9:05 PM
Sharing good practice to run complex radio-immuno conjugate trials in the UK to accelerate drug development and improve outcomes of cancer patients. @ecmc.bsky.social @icr.ac.uk @icrdduiit.bsky.social @nihr.bsky.social @cruk.bsky.social
May 7, 2025 at 11:19 AM
Professor Paul Workman, fellow of AACR, talking on the urgency in developing chemical probes to fight cancer. #AACR2025 @icr.ac.uk
April 29, 2025 at 11:58 PM
End of a long day at AACR. Presented using patient derived organoids to understand and refine mechanisms of synergy of avutometinib and defactinb combination in low grade ovarian, an area of unmet need. @icr.ac.uk @crukconvergence.bsky.social @nihr.bsky.social @ecmc-uk.bsky.social
April 29, 2025 at 11:51 PM
Masterclass in next generation ADCs! ED11 #AACR2025 worth watching online if you missed it.
April 26, 2025 at 4:35 PM
Only at #AACR 2025, Love the commitment!!!
April 26, 2025 at 4:24 PM
#AACR2025 has begun. Educational sessions on plasticity/drug resistance and models of cancer evolution. Feel the buzz! @icr.ac.uk @cancerresearchuk.org @nihr.bsky.social
April 25, 2025 at 11:55 PM
Happy retirement to my wife Jane, joined nurse training 42 years ago, worked across several NHS trusts and Australian public hospitals on clinical trials of carboplatin, VP16 (etoposide), GCSF, ondansetron and CHART RT in clinic. Worked in tral management @icr since 2005. Time to put up your feet!
February 26, 2025 at 7:00 PM
www.icr.ac.uk/about-us/icr... Blog about projects @icrlondon.bsky.social in ovarian cancer. Its only the tip of the iceberg, there are many exciting projects too early to talk about! Blessed to be a small cog in the big wheel of progress in cancer research at my institution and beyond…
January 24, 2025 at 6:16 AM
Unfolded protein response meets AR transcription. We need to think out the box to tackle known oncogenic drivers. Great piece of work from my colleague @AdamSharpMedOnc out this week aacrjournals.org/clincancerre... @icrlondon.bsky.social @theaacr.bsky.social
NXP800 activates the unfolded protein response, altering AR and E2F function to impact castration-resistant prostate cancer growth
Abstract. Purpose: Advanced prostate cancer (PCa) is invariably fatal with the androgen receptor (AR) being a major therapeutic target. AR signaling inhibitors have improved overall survival for men w...
aacrjournals.org
January 11, 2025 at 6:12 AM
Very interesting personalized m-RNA cancer vaccine paper in nature medicine www.nature.com/articles/s41... published this week establishing proof concept of the technology. Trial was led by my colleague Juantia Lopez and our unit was involved as part of an international clinical trial.
Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial - Nature Medicine
In this phase 1 trial, patients with locally advanced or metastatic solid tumors were treated with the individualized mRNA neoantigen-specific immunotherapy (iNeST) autogene cevumeran alone or in comb...
www.nature.com
January 8, 2025 at 6:05 AM